NEW YORK (GenomeWeb) – Theranostics Health today announced an agreement with Avera Health to expand research and commercial collaborations on the firm's TheraLink Assay.
The proteomic panel measures the activation of several drug targets and biomarkers associated with commonly prescribed cancer therapies to monitor treatment response.
Under the terms of the agreement, South Dakota-based Avera Health Plan will provide provisional coverage and reimbursement for the TheraLink Assay for its employees and their dependents as part of a one-year evaluation program. Meanwhile, Avera Cancer Institute will continue clinical utility studies using the TheraLink Assay in its personalized medicine research program.
"The TheraLink Assay provides uniquely valuable information that is instrumental to our program as we tailor cancer treatment to the specific proteins targeted that are active in each patient's tumor," Avera Cancer Institute VP of Molecular Medicine Brian Leyland-Jones said in a statement.
Financial details of the agreement were not disclosed.
Rockville, Md.-based Theranostics launched its first test, TheraLink HER, in June 2013 and has targeted reimbursements to grow revenue from the test.